Effects of troglitazone on serum lipids lipoproteins, and hyperinsulinemia in Watanabe heritable hyperlipidemic rabbits

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 11, 1997, Pages 876-887

  Saku, Keijiro ^a   Zhang, Bo ^a   Ohta, Takao ^b   Arakawa, Kikuo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Hyperinsulinemia; Insulin sensitivity; Lipoproteins; Troglitazone; Watanabe heritable hyperlipidemic (WHHL) rabbits

Indexed keywords

INSULIN; LIPID; LIPOPROTEIN; TRIACYLGLYCEROL; TROGLITAZONE; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOPROTEIN METABOLISM; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0031406167     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80054-9     Document Type: Article

References (38)

1. Krone W, Muller Wieland D, Wirth H. Dyslipoproteinemia and metabolic syndrome. Effects of insulin resistance and hyperinsulinemia on lipid metabolism. Fortschr Med. 1992;110:645-648.
2. Muller Wieland D, Krone W. Disorders of lipid metabolism in insulin resistance. Herz. 1995;20:33-46.
3. Florez H, Valbuena H, Ryder E, et al. Dyslipidemia and hyperinsulinemia in normoglycemic-obese relatives of patients with non-insulin dependent diabetes mellitus. Invest Clin. 1995;36:131-147.
4. Zhang B, Saku K, Hirata K, et al. Insulin resistance observed in WHHL rabbits. Atherosclerosis. 1991;91:277-278.
5. Klimes I, Vrana A, Kunes J, et al. Hereditary hypertriglyceridemic rat: A new animal model of metabolic alterations in hypertension. Blood Press. 1995;4:137-142.
6. Mathe D. Dyslipidemia and diabetes: Animal model. Diabetes Metabol. 1995;21:106-111.
7. Del Prato S. Hyperinsulinism. Causes and mechanism. Presse Med. 1992;21:1312-1317.
8. Howard G, O'Leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. Circulation. 1996;93:1809-1817.
9. Lee MK, Miles PDG, Khoursheed M, et al. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes. 1994;43:1435-1439.
10. Mimura K, Umeda F, Hiramatsu S, et al. Effects of a new oral hypoglycemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabetic Med. 1994;11:685-691.
11. Zhang B, Saku K, Hirata K, et al. Quantitative characterization of insulin-glucose response in Watanabe heritable hyperlipidemic and cholesterol-fed rabbits and the effect of cilazapril. Metabolism. 1994;43:360-366.
12. Fujiwara T, Yoshioka S, Yoshioka T, et al. Characterization of new oral antidiabetic agent CS-045: Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 1988;37: 1549-1558.
13. Iwamoto Y, Kuzuya T, Matsuda A, et al. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care. 1991; 14:1083-1086.
14. Suter SL, Nolan JJ, Wallace P, et al. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 1992;15:193-203.
15. Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. NEJM. 1994;331:1188-1193.
16. Zhang B, Saku K, Arakawa K. Quantification of the effects of troglitazone on insulin sensitivity and B-cell function in Watanabe heritable hyperlipidemic rabbits: A minimal model analysis. Metabolism. 1997;46:273-281.
17. Ogihara T, Rakugi H, Ikegami H, et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens. 1995;8:316-320.
18. Yoshioka S, Nishino H, Shiraki T, et al. Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism. 1993;42:75-80.
19. Chabot V. Syndrome "X". Schweiz Rundsch Med Prax. 1993;82:858-863.
20. Bergman RN, Ider YZ, Bowden C, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol. 1979;236:E667-E677.
21. Eggstein M, Kreutz FH. Eine neue Bestimmung der Neutralfette in Blutserum und Gewebe. I. Mit Prinzip, Durchfuhrung und Besprechung der Methode. Klin Wochenschr. 1966;44:262-264.
22. Allain CC, Poon LS, Chan CS, et al. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. Clin Chem. 1974;20:470-475.
23. 2+, and an anion-exchange resin. Clin Chem. 1978;24:1504-1508.
24. SAS Institute, Inc. SAS Procedures Guide, Version 6, Third Edition. Cary, NC: SAS Institute, Inc; 1990.
25. SAS Institute, Inc. SAS/STAT User's Guide, Version 6, Fourth Edition. Cary, NC: SAS Institute, Inc; 1990.
26. Kahn SE, Prigeon RL, McCulloch D, et al. Quantification of the relationship between insulin sensitivity and B-cell function in human subjects. Evidence for a hyperbolic function. Diabetes. 1993;42:1663-1672.
27. Abel ED, Ledingham JG. Impaired glucose tolerance in hypertension is associated with impaired insulin release independently of changes in insulin sensitivity. J Hypertens. 1994;12:1265-1273.
28. Rosenfeld ME, Tsukada T, Gown AM, Ross R. Fatty streak initiation in Watanabe heritable hyperlipidemic and comparably hypercholesterolemic fat-fed rabbits. Atherosclerosis. 1987;7:9-23.
29. Laakso M. Dyslipidaemias, insulin resistance and atherosclerosis. Ann Med. 1992;24: 505-509.
30. Havel RJ, Kita T, Kotite L, et al. Concentration and composition of lipoproteins in blood plasma of the WHHL rabbit. An animal model of human familial hypercholesterolemia. Arteriosclerosis. 1982;2:467-474.
31. Wakasugi T, Mabuchi H, Sakai Y, et al. ApoVLDL of the Watanabe heritable hyperlipidemic rabbit and the cholesterol-fed rabbit. J Lipid Res. 1984;25:246-253.
32. Zhang B, Saku K, Hirata K, et al. Insulin response in WHHL and cholesterol-fed rabbits. Jpn Clin Metab (Meeting Report). 1993;29:174-175.
33. Mykkanen L, Kuusisto J, Haffner S, et al. Hyperinsulinemia predicts multiple atherogenic changes in lipoproteins in elderly subjects. Arterioscler Thromb. 1994;14:518-526.
34. Kita T, Brown MS, Bilheimer DW, Goldstein JL. Delayed clearance of very low density and intermediate density lipoproteins with enhanced conversion to low density lipoprotein in WHHL rabbits. Proc Natl Acad Sci USA. 1982;79:5693-5697.
35. Tanzawa K, Shimada Y, Kuroda M, et al. WHHL-rabbits: A low density lipoprotein receptor-deficient animal model for familial hypercholesterolemia. FEBS Lett. 1980;118: 81-84.
36. Lefkos N, Efthimiadis A, Liatsis I, et al. Hemodynamic and biochemical changes after chronic administration of cilazapril to hypertensive patients. Cardiology. 1993;82:249-258.
37. Oska A, Gajdos M, Fedelesova V, et al. Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension. J Cardiovasc Pharmacol. 1994;23:79-86.
38. Ibrahimi A, Teboul L, Gaillard D, et al. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol Pharmacol. 1994;46:1070-1076.